Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

227.50 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 607
Open 227.50
Bid (Size) 227.20 (700)
Ask (Size) 228.60 (200)
Prev. Close 227.50
Today's Range 227.50 - 227.50
52wk Range 164.39 - 244.81
Shares Outstanding N/A
Dividend Yield 3.04%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The Great Rotation: Healthcare Emerges as the S&P 500’s New Crown Jewel in 2026
As of February 12, 2026, the financial landscape has undergone a tectonic shift, with the healthcare sector decisively seizing the mantle of market leadership. After years of dominance by high-flying... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
1 Reason I'm Never Selling AbbVie Stock ↗
This Dividend King has staying power. 
Via The Motley Fool
Topics Intellectual Property

Performance

YTD
-0.8%
-0.8%
1 Month
+3.1%
+3.1%
3 Month
-2.1%
-2.1%
6 Month
+11.1%
+11.1%
1 Year
+17.9%
+17.9%

More News

Read More
News headline image
Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss
Via Finterra
Topics Economy Intellectual Property
AbbVie Inc. (NYSE:ABBV) Raises 2026 Outlook Despite Q4 Revenue Miss ↗
Via Chartmill
News headline image
The 5 Most Interesting Analyst Questions From AbbVie’s Q4 Earnings Call
Via StockStory
Topics Earnings
News headline image
Silver and Gold Prices Are Volatile. Buy This ETF for Safety This Year ↗
Via The Motley Fool
Topics ETFs
News headline image
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
Via FinancialNewsMedia
News headline image
3 Market-Beating Stocks to Research Further
Via StockStory
News headline image
The Great Pipeline Grab: Life Sciences Deal Volume Skyrockets 82% as Big Pharma Battles the Patent Cliff
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal ↗
Via MarketBeat
News headline image
ABBV Q4 Deep Dive: Immunology and Neuroscience Growth Offset Aesthetics Softness and Pricing Headwinds
Via StockStory
News headline image
AbbVie (ABBV) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
Gapping S&P500 stocks in Wednesday's session ↗
Via Chartmill
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
AbbVie’s (NYSE:ABBV) Q4 CY2025: Beats On Revenue
Via StockStory
News headline image
2 Healthcare Dividend Stocks That are Just What the Doctor Ordered ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
AbbVie (ABBV) Q4 Earnings: What To Expect
Via StockStory
News headline image
The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate
Via MarketMinute
Topics ETFs Government Initial Public Offering
News headline image
Where Will AbbVie Be in 5 Years? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
2 No-Brainer Dividend Stocks to Buy Hand Over Fist ↗
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
Better Long-Term Buy: This Emerging Player or the Industry Leader? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Q3 Earnings Highs And Lows: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
News headline image
Why AbbVie Stock Trounced the Market in 2025 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Eli Lilly Reinforces Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences
Via MarketMinute
News headline image
Why Revolution Medicines Stock Plummeted by Almost 17% Today ↗
Via The Motley Fool

Frequently Asked Questions

Is AbbVie publicly traded?
Yes, AbbVie is publicly traded.
What exchange does AbbVie trade on?
AbbVie trades on the New York Stock Exchange
What is the ticker symbol for AbbVie?
The ticker symbol for AbbVie is ABBV on the New York Stock Exchange
What is the current price of AbbVie?
The current price of AbbVie is 227.50
When was AbbVie last traded?
The last trade of AbbVie was at 02/12/26 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.